Hormonal
Cagrilintide-Semaglutide (CagriSema) produces superior weight loss and metabolic improvements compared to monotherapies and placebo in adults with overweight or obesity, with or without type 2 diabetes.
CagriSema is a potent, non-surgical weight loss option that significantly outperforms current GLP-1 monotherapies. It requires weekly (implied) injections and lifestyle changes. Expect transient GI side effects that usually subside. It is suitable for those with BMI ≥30 (or ≥27 with comorbidities), including those with T2D.
These results were significantly superior to Semaglutide monotherapy (14.8% achieving ≥25% weight loss) and Cagrilintide monotherapy (6.5% achieving ≥25% weight loss).
Why this rating
Based on large-scale Phase 3a multicenter double-blind trials (REDEFINE 1 and 2).
Source
The next frontier in metabolic health: Cagrilintide-Semaglutide and the evolving landscape of therapies
Yuxin Wang et al. · The Innovation Medicine · 2025
DOI 10.59717/j.xinn-med.2025.100150
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →